Disease · MONDO_0006003
uterine corpus cancer
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. uterine corpus cancer. Diseases, record MONDO_0006003. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006003
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
body of uterus cancer, cancer of body of uterus, cancer of the corpus uteri, corpus uteri cancer, endometrial cancer, malignant body of uterus neoplasm, malignant neoplasm of body of uterus, uterine (including endometrial) cancer
- Open Targets
Drugs20
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ABEMACICLIB | CHEMBL3301610 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DATOPOTAMAB DERUXTECAN | CHEMBL4297939 | Antibody drug conjugate | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LENVATINIB | CHEMBL1289601 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LETROZOLE | CHEMBL1444 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LEUCOVORIN | CHEMBL1679 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 20
See all 20 drugsTargets30
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | 2 | Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 1 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| TYMS | Thymidylate synthase | 2 | Thymidylate synthase inhibitor | Phase 2 | https://conductscience.org/library/genes/7298 | Drugs and targets |
| CDK4 | Cyclin-dependent kinase 4 | 1 | Cyclin-dependent kinase 4 inhibitor | Phase 2 | https://conductscience.org/library/genes/1019 | Drugs and targets |
| CDK6 | Cyclin-dependent kinase 6 | 1 | Cyclin-dependent kinase 6 inhibitor | Phase 2 | https://conductscience.org/library/genes/1021 | Drugs and targets |
| CYP19A1 | Aromatase | 1 | Cytochrome P450 19A1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1588 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Phase 1 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor agonist | Phase 2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
1 to 10 of 30
See all 30 targetsTrials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03189446 | Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer | Phase 2 | 39 | 2021-01-12 | Endometrial Cancer, Papillary Serous, Clear Cell Endometrial Cancer | CARBOPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT05263492 | Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer | Phase 2 | 4 | 2025-10-02 | Endometrial Cancer, Mismatch Repair-Proficient, Recurrent Endometrial Cancer | LENVATINIB, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05489211 | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | Phase 2 | 454 | Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer | BEVACIZUMAB, CAPECITABINE, CARBOPLATIN, CISPLATIN, DATOPOTAMAB DERUXTECAN, FLUOROURACIL, LEUCOVORIN, PREDNISONE, RILVEGOSTOMIG, VOLRUSTOMIG | Its record names the disease | ClinicalTrials.gov | |
| NCT04188548 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer | Phase 1 | 379 | Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer | ABEMACICLIB, ALPELISIB, EVEROLIMUS, IMLUNESTRANT, PERTUZUMAB, TRASTUZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06366347 | ALPINE: Maintenance Letrozole/Abemaciclib | Phase 2 | 32 | Endometrial Cancer, Recurrent Endometrial Cancer, TP53 | ABEMACICLIB, LETROZOLE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006003
GET https://conductscience.org/api/diseases/v1/MONDO_0006003/targets?page=2